Sensus Healthcare (NASDAQ:SRTS) Price Target Raised to $11.00

Sensus Healthcare (NASDAQ:SRTS) had its price target raised by HC Wainwright from $10.00 to $11.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.11 EPS, FY2024 earnings at $0.42 EPS, Q1 2025 earnings at $0.14 EPS, Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.20 EPS and FY2025 earnings at $0.52 EPS.

Separately, Maxim Group raised their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th.

Sensus Healthcare Stock Up 0.1 %

Sensus Healthcare stock opened at $8.95 on Monday. The stock has a market cap of $146.69 million, a P/E ratio of 15.39 and a beta of 1.04. The company’s 50-day moving average price is $6.53 and its two-hundred day moving average price is $6.05. Sensus Healthcare has a twelve month low of $2.05 and a twelve month high of $9.20.

Institutional Trading of Sensus Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its position in Sensus Healthcare by 34.4% in the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock worth $2,087,000 after buying an additional 100,294 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Sensus Healthcare by 128.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock worth $888,000 after buying an additional 93,511 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Sensus Healthcare by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after purchasing an additional 11,525 shares during the last quarter. Sachetta LLC lifted its stake in shares of Sensus Healthcare by 12.9% in the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company’s stock valued at $631,000 after acquiring an additional 13,544 shares during the last quarter. Finally, Marshall Wace LLP boosted its stake in shares of Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock valued at $412,000 after purchasing an additional 46,732 shares during the period. 25.30% of the stock is owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.